[go: up one dir, main page]

ECSP18061667A - PYRIMIDINES SUBSTITUTED WITH ARILO FOR USE IN INFECTION BY VIRUS INFLUENZA - Google Patents

PYRIMIDINES SUBSTITUTED WITH ARILO FOR USE IN INFECTION BY VIRUS INFLUENZA

Info

Publication number
ECSP18061667A
ECSP18061667A ECSENADI201861667A ECDI201861667A ECSP18061667A EC SP18061667 A ECSP18061667 A EC SP18061667A EC SENADI201861667 A ECSENADI201861667 A EC SENADI201861667A EC DI201861667 A ECDI201861667 A EC DI201861667A EC SP18061667 A ECSP18061667 A EC SP18061667A
Authority
EC
Ecuador
Prior art keywords
arilo
infection
virus influenza
pyrimidines substituted
pyrimidines
Prior art date
Application number
ECSENADI201861667A
Other languages
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP18061667A publication Critical patent/ECSP18061667A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a compuestos que tienen la estructura de fórmula (I) que se pueden utilizar para el tratamiento de infecciones de la gripe o contra estas.The invention relates to compounds having the structure of formula (I) which can be used for the treatment of influenza infections or against them.

ECSENADI201861667A 2016-01-20 2018-08-15 PYRIMIDINES SUBSTITUTED WITH ARILO FOR USE IN INFECTION BY VIRUS INFLUENZA ECSP18061667A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16152095 2016-01-20

Publications (1)

Publication Number Publication Date
ECSP18061667A true ECSP18061667A (en) 2018-10-31

Family

ID=55345663

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201861667A ECSP18061667A (en) 2016-01-20 2018-08-15 PYRIMIDINES SUBSTITUTED WITH ARILO FOR USE IN INFECTION BY VIRUS INFLUENZA

Country Status (20)

Country Link
US (2) US10611755B2 (en)
EP (1) EP3405466B1 (en)
JP (1) JP6989509B2 (en)
KR (1) KR20180100375A (en)
CN (1) CN108473477B (en)
AU (1) AU2017209925B2 (en)
BR (1) BR112018014794A2 (en)
CA (1) CA3010327A1 (en)
CL (1) CL2018001960A1 (en)
CO (1) CO2018007669A2 (en)
DK (1) DK3405466T3 (en)
EA (1) EA201891666A1 (en)
EC (1) ECSP18061667A (en)
ES (1) ES2850575T3 (en)
HR (1) HRP20202051T1 (en)
HU (1) HUE053078T2 (en)
LT (1) LT3405466T (en)
MX (1) MX381314B (en)
SI (1) SI3405466T1 (en)
WO (1) WO2017125506A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201405826RA (en) 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR20180087290A (en) 2015-11-27 2018-08-01 얀센 사이언시즈 아일랜드 유씨 Heterocyclic indole for use in influenza virus infection
JP6989509B2 (en) * 2016-01-20 2022-01-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Aryl-substituted pyrimidines for use in influenza virus infection
CN107759571B (en) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
CN109641868B (en) 2016-08-30 2021-12-03 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
US10987354B2 (en) 2016-12-15 2021-04-27 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN110446711B (en) 2017-03-02 2022-02-15 广东东阳光药业有限公司 Inhibitors of influenza virus replication and uses thereof
EP4470609A3 (en) * 2019-01-18 2025-03-12 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
MX2021008661A (en) 2019-01-18 2021-08-19 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USE THEREOF.
CN119504738A (en) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 Compounds as MRGPRX2 antagonists and preparation methods and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080063809A (en) 2005-09-30 2008-07-07 버텍스 파마슈티칼스 인코포레이티드 Deazapurine, useful as an inhibitor of Janus kinase
MX2009008540A (en) * 2007-02-08 2009-08-18 Tibotec Pharm Ltd Pyrimidine substituted macrocyclic hcv inhibitors.
SG10201405826RA (en) * 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
RU2013132681A (en) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед INFLUENZA VIRUS REPLICATION INHIBITORS
CA2822062A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
PH12013502033A1 (en) * 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
EP2858984A1 (en) * 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
WO2014060411A1 (en) * 2012-10-16 2014-04-24 Janssen R&D Ireland Rsv antiviral compounds
UA118751C2 (en) * 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі 2-aminopyrimidine derivatives for the treatment of viral infections
KR20180087290A (en) 2015-11-27 2018-08-01 얀센 사이언시즈 아일랜드 유씨 Heterocyclic indole for use in influenza virus infection
JP6989509B2 (en) * 2016-01-20 2022-01-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Aryl-substituted pyrimidines for use in influenza virus infection

Also Published As

Publication number Publication date
US11117887B2 (en) 2021-09-14
CL2018001960A1 (en) 2018-08-31
AU2017209925A1 (en) 2018-07-12
CN108473477A (en) 2018-08-31
US20190047989A1 (en) 2019-02-14
DK3405466T3 (en) 2021-02-01
LT3405466T (en) 2021-01-25
AU2017209925B2 (en) 2021-04-08
EP3405466A1 (en) 2018-11-28
US10611755B2 (en) 2020-04-07
SI3405466T1 (en) 2021-02-26
WO2017125506A1 (en) 2017-07-27
MX2018008803A (en) 2018-11-09
KR20180100375A (en) 2018-09-10
HRP20202051T1 (en) 2021-02-19
MX381314B (en) 2025-03-12
CA3010327A1 (en) 2017-07-27
ES2850575T3 (en) 2021-08-30
BR112018014794A2 (en) 2018-12-11
JP2019507119A (en) 2019-03-14
CN108473477B (en) 2021-10-22
CO2018007669A2 (en) 2018-08-10
JP6989509B2 (en) 2022-01-05
EP3405466B1 (en) 2020-11-18
EA201891666A1 (en) 2019-01-31
HUE053078T2 (en) 2021-06-28
US20200231577A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
ECSP18061667A (en) PYRIMIDINES SUBSTITUTED WITH ARILO FOR USE IN INFECTION BY VIRUS INFLUENZA
MX2017001752A (en) INDOLES FOR USE IN INFECTION WITH THE VIRUS OF THE FLU.
CL2017000533A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CL2016001120A1 (en) Compounds derived from pyrrolo1,2-f1,2,4triazine, a pharmaceutical composition that comprises them and their use in the treatment of a syncytial virus infection intermediary compounds. pct
CL2015003615A1 (en) Substituted nucleosides, nucleotides and analogs thereof.
CL2016000493A1 (en) Hcv polymerase inhibitors
MX2017008720A (en) DERIVATIVES AND METHODS FOR TREATMENT OF INFECTIONS BY HEPATITIS B.
CL2015003298A1 (en) Novel bridged heteroaryl dihydropyrimidines in 6 for the treatment and prophylaxis of hepatitis B virus infection
CL2015001864A1 (en) Compounds derived from substituted spiropyrido [1,2-a] pyrazine, as hiv integrase inhibitors; pharmaceutical composition that includes them; and its use for the prophylaxis or treatment of a hiv infection.
MX2016009337A (en) DERIVATIVES OF AZEPANO AND METHODS TO TREAT INFECTIONS BY HEPATITIS B.
CL2014001956A1 (en) Compounds derived from amidine-substituted beta-lactams; method for its preparation; medicine that understands them; and its use for the treatment and / or prophylaxis of bacterial infections.
CR20150337A (en) DERIVATIVES OF PIRIMIDINONE AND ITS USE IN THE TREATMENT, IMPROVEMENT OR PREVENTION OF A VIRAL DISEASE
CL2017002482A1 (en) Heterocyclic compounds and their use in the prevention or treatment of bacterial infections
DOP2016000336A (en) ISOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION
EA201891278A1 (en) HETEROCYCLIC INDOLS TO BE USED FOR INFECTION CAUSED BY THE FLU VIRUS
CL2020001147A1 (en) Antibacterial compounds
EA201891576A1 (en) FUNCTIONALIZED PENTANE ACIDS FOR APPLICATION IN INFECTIONS CAUSED BY THE VIRUS OF THE FLU
BR112017008496A2 (en) compounds for use in anthelmintic treatment
UY36221A (en) ISOINDOLINONE DERIVATIVES
CL2017002451A1 (en) Novel heterocyclic compounds and their use in the prevention or treatment of bacterial infections
CL2017002803A1 (en) Heterocyclic compounds and their use in the prevention or treatment of bacterial infections
CL2017000151A1 (en) Pyridone derivatives
UY36196A (en) COMPOUNDS TO USE IN ANTIHELMINTIC TREATMENT
CL2017002449A1 (en) Heterocyclic compounds and their use in the prevention or treatment of bacterial infections
CL2016001977A1 (en) Composition comprising plasma-derived igm and its use for the treatment or prevention of immune conditions.